|Day's range||0.028 - 0.030|
|52-week range||0.028 - 0.044|
|PE ratio (TTM)||-7.25|
|Earnings date||1 Mar. 2016 - 5 Mar. 2016|
|Dividend & yield||N/A (N/A)|
|1y target est||0.04|
back SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ('Prima' or the 'Company') today announced interim data for its TACTI-mel (Two ACTive Immunotherapeutics in melanoma) clinical trial program ...
Prima BioMed Announces Data from IMP321 AIPAC Clinical Trial in Breast Cancer The text version of this document is not available at the moment. The original content was posted at original link . Prima ...
back English SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD), announces that it has received approval from the Competent Authority and Ethics Committee in the UK for its Phase IIb, AIPAC ...